Exact Mass: 471.4202

Exact Mass Matches: 471.4202

Found 80 metabolites which its exact mass value is equals to given mass value 471.4202, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

3-Hydroxyeicosanoylcarnitine

3-[(3-Hydroxyicosanoyl)oxy]-4-(trimethylammonio)butanoic acid

C27H53NO5 (471.3924)


3-Hydroxyeicosanoylcarnitine is an acylcarnitine. More specifically, it is an 3-hydroxyeicosanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-Hydroxyeicosanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 3-Hydroxyeicosanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

2-Hydroxyicosanoylcarnitine

3-[(2-hydroxyicosanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C27H53NO5 (471.3924)


2-hydroxyicosanoylcarnitine is an acylcarnitine. More specifically, it is an 2-hydroxyicosanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 2-hydroxyicosanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 2-hydroxyicosanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

12-Hydroxyicosanoylcarnitine

3-[(12-hydroxyicosanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C27H53NO5 (471.3924)


12-hydroxyicosanoylcarnitine is an acylcarnitine. More specifically, it is an 12-hydroxyicosanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 12-hydroxyicosanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 12-hydroxyicosanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

15-Hydroxyicosanoylcarnitine

15-Hydroxyicosanoylcarnitine

C27H53NO5 (471.3924)


15-hydroxyicosanoylcarnitine is an acylcarnitine. More specifically, it is an 15-hydroxyicosanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 15-hydroxyicosanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 15-hydroxyicosanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Daphnioldhanin F

Daphnioldhanin F

C30H49NO3 (471.3712)


   

Tetrahydrodeoxyoxolucidine A

Tetrahydrodeoxyoxolucidine A

C30H53N3O (471.4188)


   

secodaphniphylline

secodaphniphylline

C30H49NO3 (471.3712)


   

methyl (Z)-N-13-docosenoylanthranilate|methyl N-Delta13-docosenoylanthranilate

methyl (Z)-N-13-docosenoylanthranilate|methyl N-Delta13-docosenoylanthranilate

C30H49NO3 (471.3712)


   

N-(2-phenylethyl) tetracosanamide

N-(2-phenylethyl) tetracosanamide

C32H57NO (471.444)


   

CAR 20:0;O

3-[(3-hydroxyicosanoyl)oxy]-4-(trimethylammonio)butanoate;3-hydroxyarachidoylcarnitine;3-hydroxyicosanoylcarnitine;O-(3-hydroxyarachidoyl)carnitine;O-(3-hydroxyeicosanoyl)carnitine;O-(3-hydroxyicosanoyl)carnitine

C27H53NO5 (471.3924)


   

n-Hexadecyl-trimethyl-ammonium-3-hydroxy-2-naphthoate

n-Hexadecyl-trimethyl-ammonium-3-hydroxy-2-naphthoate

C30H49NO3 (471.3712)


   

2-Hydroxyicosanoylcarnitine

2-Hydroxyicosanoylcarnitine

C27H53NO5 (471.3924)


   

12-Hydroxyicosanoylcarnitine

12-Hydroxyicosanoylcarnitine

C27H53NO5 (471.3924)


   

15-Hydroxyicosanoylcarnitine

15-Hydroxyicosanoylcarnitine

C27H53NO5 (471.3924)


   

(17Z,20Z,23Z,26Z)-dotriacontatetraenoate

(17Z,20Z,23Z,26Z)-dotriacontatetraenoate

C32H55O2- (471.4202)


A polyunsaturated fatty acid anion that is the conjugate base of (17Z,20Z,23Z,26Z)-dotriacontatetraenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

2-Aminononacosane-1,3,4-triol

2-Aminononacosane-1,3,4-triol

C29H61NO3 (471.4651)


   

(7Z,10Z,13Z,16Z,19Z)-N-[(E)-1,3-dihydroxyoct-4-en-2-yl]docosa-7,10,13,16,19-pentaenamide

(7Z,10Z,13Z,16Z,19Z)-N-[(E)-1,3-dihydroxyoct-4-en-2-yl]docosa-7,10,13,16,19-pentaenamide

C30H49NO3 (471.3712)


   

(4Z,7Z,10Z,13Z,16Z,19Z)-N-(1,3-dihydroxyoctan-2-yl)docosa-4,7,10,13,16,19-hexaenamide

(4Z,7Z,10Z,13Z,16Z,19Z)-N-(1,3-dihydroxyoctan-2-yl)docosa-4,7,10,13,16,19-hexaenamide

C30H49NO3 (471.3712)


   

(5Z,8Z,11Z,14Z,17Z)-N-[(E)-1,3-dihydroxydec-4-en-2-yl]icosa-5,8,11,14,17-pentaenamide

(5Z,8Z,11Z,14Z,17Z)-N-[(E)-1,3-dihydroxydec-4-en-2-yl]icosa-5,8,11,14,17-pentaenamide

C30H49NO3 (471.3712)


   

(3Z,6Z,9Z,12Z,15Z)-N-[(E)-1,3-dihydroxydodec-4-en-2-yl]octadeca-3,6,9,12,15-pentaenamide

(3Z,6Z,9Z,12Z,15Z)-N-[(E)-1,3-dihydroxydodec-4-en-2-yl]octadeca-3,6,9,12,15-pentaenamide

C30H49NO3 (471.3712)


   

(7Z,10Z,13Z)-N-[(4E,8E,12E)-1,3-dihydroxytetradeca-4,8,12-trien-2-yl]hexadeca-7,10,13-trienamide

(7Z,10Z,13Z)-N-[(4E,8E,12E)-1,3-dihydroxytetradeca-4,8,12-trien-2-yl]hexadeca-7,10,13-trienamide

C30H49NO3 (471.3712)


   

(6Z,9Z,12Z,15Z)-N-[(4E,8E)-1,3-dihydroxydodeca-4,8-dien-2-yl]octadeca-6,9,12,15-tetraenamide

(6Z,9Z,12Z,15Z)-N-[(4E,8E)-1,3-dihydroxydodeca-4,8-dien-2-yl]octadeca-6,9,12,15-tetraenamide

C30H49NO3 (471.3712)


   

(4Z,7Z,10Z,13Z)-N-[(4E,8E)-1,3-dihydroxytetradeca-4,8-dien-2-yl]hexadeca-4,7,10,13-tetraenamide

(4Z,7Z,10Z,13Z)-N-[(4E,8E)-1,3-dihydroxytetradeca-4,8-dien-2-yl]hexadeca-4,7,10,13-tetraenamide

C30H49NO3 (471.3712)


   

Cer 9:0;3O/18:1;(2OH)

Cer 9:0;3O/18:1;(2OH)

C27H53NO5 (471.3924)


   

Cer 8:0;3O/19:1;(2OH)

Cer 8:0;3O/19:1;(2OH)

C27H53NO5 (471.3924)


   

Cer 11:0;3O/16:1;(2OH)

Cer 11:0;3O/16:1;(2OH)

C27H53NO5 (471.3924)


   

Cer 12:1;3O/15:0;(2OH)

Cer 12:1;3O/15:0;(2OH)

C27H53NO5 (471.3924)


   

Cer 13:0;3O/14:1;(2OH)

Cer 13:0;3O/14:1;(2OH)

C27H53NO5 (471.3924)


   

Cer 13:1;3O/14:0;(2OH)

Cer 13:1;3O/14:0;(2OH)

C27H53NO5 (471.3924)


   

Cer 12:0;3O/15:1;(2OH)

Cer 12:0;3O/15:1;(2OH)

C27H53NO5 (471.3924)


   

N-(1,3,4-trihydroxyhexadecan-2-yl)dodecanamide

N-(1,3,4-trihydroxyhexadecan-2-yl)dodecanamide

C28H57NO4 (471.4287)


   

N-(1,3,4-trihydroxypentadecan-2-yl)tridecanamide

N-(1,3,4-trihydroxypentadecan-2-yl)tridecanamide

C28H57NO4 (471.4287)


   

N-(1,3,4-trihydroxytetradecan-2-yl)tetradecanamide

N-(1,3,4-trihydroxytetradecan-2-yl)tetradecanamide

C28H57NO4 (471.4287)


   

Cer 15:1;3O/12:0;(2OH)

Cer 15:1;3O/12:0;(2OH)

C27H53NO5 (471.3924)


   

Cer 14:0;2O/14:0;(3OH)

Cer 14:0;2O/14:0;(3OH)

C28H57NO4 (471.4287)


   

Cer 15:0;3O/12:1;(2OH)

Cer 15:0;3O/12:1;(2OH)

C27H53NO5 (471.3924)


   

Cer 15:0;2O/13:0;(2OH)

Cer 15:0;2O/13:0;(2OH)

C28H57NO4 (471.4287)


   

Cer 16:0;2O/12:0;(3OH)

Cer 16:0;2O/12:0;(3OH)

C28H57NO4 (471.4287)


   

Cer 16:0;2O/12:0;(2OH)

Cer 16:0;2O/12:0;(2OH)

C28H57NO4 (471.4287)


   

Cer 14:1;3O/13:0;(2OH)

Cer 14:1;3O/13:0;(2OH)

C27H53NO5 (471.3924)


   

Cer 15:0;2O/13:0;(3OH)

Cer 15:0;2O/13:0;(3OH)

C28H57NO4 (471.4287)


   

Cer 14:0;2O/14:0;(2OH)

Cer 14:0;2O/14:0;(2OH)

C28H57NO4 (471.4287)


   

Cer 14:0;3O/13:1;(2OH)

Cer 14:0;3O/13:1;(2OH)

C27H53NO5 (471.3924)


   

3-hydroxyeicosanoylcarnitine

3-hydroxyeicosanoylcarnitine

C27H53NO5 (471.3924)


An O-acylcarnitine having 3-hydroxyeicosanoyl as the acyl substituent.

   

dotriacontatetraenoate

dotriacontatetraenoate

C32H55O2 (471.4202)


A polyunsaturated fatty acid anion that is the conjugate base of dotriacontatetraenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   
   

NA-Dopamine 22:2(13Z,16Z)

NA-Dopamine 22:2(13Z,16Z)

C30H49NO3 (471.3712)


   
   
   

Cer 14:0;O2/14:0;2OH

Cer 14:0;O2/14:0;2OH

C28H57NO4 (471.4287)


   

Cer 14:0;O2/14:0;3OH

Cer 14:0;O2/14:0;3OH

C28H57NO4 (471.4287)


   

Cer 14:0;O2/14:0;O

Cer 14:0;O2/14:0;O

C28H57NO4 (471.4287)


   

Cer 15:0;O2/13:0;2OH

Cer 15:0;O2/13:0;2OH

C28H57NO4 (471.4287)


   

Cer 15:0;O2/13:0;3OH

Cer 15:0;O2/13:0;3OH

C28H57NO4 (471.4287)


   

Cer 15:0;O2/13:0;O

Cer 15:0;O2/13:0;O

C28H57NO4 (471.4287)


   

Cer 16:0;O2/12:0;2OH

Cer 16:0;O2/12:0;2OH

C28H57NO4 (471.4287)


   

Cer 16:0;O2/12:0;3OH

Cer 16:0;O2/12:0;3OH

C28H57NO4 (471.4287)


   

Cer 16:0;O2/12:0;O

Cer 16:0;O2/12:0;O

C28H57NO4 (471.4287)


   

Cer 17:0;O2/11:0;2OH

Cer 17:0;O2/11:0;2OH

C28H57NO4 (471.4287)


   

Cer 17:0;O2/11:0;3OH

Cer 17:0;O2/11:0;3OH

C28H57NO4 (471.4287)


   

Cer 17:0;O2/11:0;O

Cer 17:0;O2/11:0;O

C28H57NO4 (471.4287)


   

Cer 18:0;O2/10:0;2OH

Cer 18:0;O2/10:0;2OH

C28H57NO4 (471.4287)


   

Cer 18:0;O2/10:0;3OH

Cer 18:0;O2/10:0;3OH

C28H57NO4 (471.4287)


   

Cer 18:0;O2/10:0;O

Cer 18:0;O2/10:0;O

C28H57NO4 (471.4287)


   

Cer 14:0;O3/14:0

Cer 14:0;O3/14:0

C28H57NO4 (471.4287)


   

Cer 15:0;O3/13:0

Cer 15:0;O3/13:0

C28H57NO4 (471.4287)


   

Cer 16:0;O3/12:0

Cer 16:0;O3/12:0

C28H57NO4 (471.4287)


   

Cer 17:0;O3/11:0

Cer 17:0;O3/11:0

C28H57NO4 (471.4287)


   

Cer 18:0;O3/10:0

Cer 18:0;O3/10:0

C28H57NO4 (471.4287)


   
   

1-{1,4-dimethyl-2,8-dioxabicyclo[3.2.1]octan-4-yl}-3-{14-isopropyl-1-methyl-12-azatetracyclo[8.6.0.0²,¹³.0³,⁷]hexadecan-2-yl}propan-1-one

1-{1,4-dimethyl-2,8-dioxabicyclo[3.2.1]octan-4-yl}-3-{14-isopropyl-1-methyl-12-azatetracyclo[8.6.0.0²,¹³.0³,⁷]hexadecan-2-yl}propan-1-one

C30H49NO3 (471.3712)


   

(1s,2s,7r,8s)-8-{2-[(1s,2r,3r,7r,10s,11r,13s,14r)-14-isopropyl-1-methyl-12-azapentacyclo[8.6.0.0²,¹³.0³,⁷.0⁷,¹¹]hexadecan-2-yl]ethyl}-1,5-dimethyl-6-oxabicyclo[3.2.1]octane-2,7-diol

(1s,2s,7r,8s)-8-{2-[(1s,2r,3r,7r,10s,11r,13s,14r)-14-isopropyl-1-methyl-12-azapentacyclo[8.6.0.0²,¹³.0³,⁷.0⁷,¹¹]hexadecan-2-yl]ethyl}-1,5-dimethyl-6-oxabicyclo[3.2.1]octane-2,7-diol

C30H49NO3 (471.3712)


   

5-[(1-ethyl-7-methyl-octahydro-2h-quinolin-5-yl)methyl]-11,14-dimethyl-6,14-diazatetracyclo[7.6.2.0²,⁷.0¹³,¹⁷]heptadecan-2-ol

5-[(1-ethyl-7-methyl-octahydro-2h-quinolin-5-yl)methyl]-11,14-dimethyl-6,14-diazatetracyclo[7.6.2.0²,⁷.0¹³,¹⁷]heptadecan-2-ol

C30H53N3O (471.4188)


   

(1s,2s,5s,7r,8s)-8-{2-[(1s,2r,3r,7r,10s,11r,13s,14r)-14-isopropyl-1-methyl-12-azapentacyclo[8.6.0.0²,¹³.0³,⁷.0⁷,¹¹]hexadecan-2-yl]ethyl}-1,5-dimethyl-6-oxabicyclo[3.2.1]octane-2,7-diol

(1s,2s,5s,7r,8s)-8-{2-[(1s,2r,3r,7r,10s,11r,13s,14r)-14-isopropyl-1-methyl-12-azapentacyclo[8.6.0.0²,¹³.0³,⁷.0⁷,¹¹]hexadecan-2-yl]ethyl}-1,5-dimethyl-6-oxabicyclo[3.2.1]octane-2,7-diol

C30H49NO3 (471.3712)


   

n-[2-(methoxycarbonyl)phenyl]docos-13-enimidic acid

n-[2-(methoxycarbonyl)phenyl]docos-13-enimidic acid

C30H49NO3 (471.3712)


   

(13z)-n-[2-(methoxycarbonyl)phenyl]docos-13-enimidic acid

(13z)-n-[2-(methoxycarbonyl)phenyl]docos-13-enimidic acid

C30H49NO3 (471.3712)


   

1-[(1r,4r,5s)-1,4-dimethyl-2,8-dioxabicyclo[3.2.1]octan-4-yl]-3-[(1s,2r,3r,7s,10s,13s,14r)-14-isopropyl-1-methyl-12-azatetracyclo[8.6.0.0²,¹³.0³,⁷]hexadecan-2-yl]propan-1-one

1-[(1r,4r,5s)-1,4-dimethyl-2,8-dioxabicyclo[3.2.1]octan-4-yl]-3-[(1s,2r,3r,7s,10s,13s,14r)-14-isopropyl-1-methyl-12-azatetracyclo[8.6.0.0²,¹³.0³,⁷]hexadecan-2-yl]propan-1-one

C30H49NO3 (471.3712)


   

8-(2-{14-isopropyl-1-methyl-12-azapentacyclo[8.6.0.0²,¹³.0³,⁷.0⁷,¹¹]hexadecan-2-yl}ethyl)-1,5-dimethyl-6-oxabicyclo[3.2.1]octane-2,7-diol

8-(2-{14-isopropyl-1-methyl-12-azapentacyclo[8.6.0.0²,¹³.0³,⁷.0⁷,¹¹]hexadecan-2-yl}ethyl)-1,5-dimethyl-6-oxabicyclo[3.2.1]octane-2,7-diol

C30H49NO3 (471.3712)


   

(1r,2s,5r,7s,9s,11r,13s,17r)-5-{[(4ar,5r,7s,8as)-1-ethyl-7-methyl-octahydro-2h-quinolin-5-yl]methyl}-11,14-dimethyl-6,14-diazatetracyclo[7.6.2.0²,⁷.0¹³,¹⁷]heptadecan-2-ol

(1r,2s,5r,7s,9s,11r,13s,17r)-5-{[(4ar,5r,7s,8as)-1-ethyl-7-methyl-octahydro-2h-quinolin-5-yl]methyl}-11,14-dimethyl-6,14-diazatetracyclo[7.6.2.0²,⁷.0¹³,¹⁷]heptadecan-2-ol

C30H53N3O (471.4188)


   

(1r,2s,5s,7s,9s,11r,13s,17r)-5-{[(4as,5r,7s,8ar)-1-ethyl-7-methyl-octahydro-2h-quinolin-5-yl]methyl}-11,14-dimethyl-6,14-diazatetracyclo[7.6.2.0²,⁷.0¹³,¹⁷]heptadecan-2-ol

(1r,2s,5s,7s,9s,11r,13s,17r)-5-{[(4as,5r,7s,8ar)-1-ethyl-7-methyl-octahydro-2h-quinolin-5-yl]methyl}-11,14-dimethyl-6,14-diazatetracyclo[7.6.2.0²,⁷.0¹³,¹⁷]heptadecan-2-ol

C30H53N3O (471.4188)